Internal Medicine · 2018 · 17 citations · 13 references
MedicineEndocrinologyNuclear MedicineAutoimmunityEndocrine OncologyImmunotherapyAdrenal DisordersEndocrine DiseaseEndocrine DisordersEndocrine ToxicityImmune-related Adverse EventsThyroid DisordersAdrenal Insufficiency SyndromesHypophysitis ImagingImmune-mediated EndocrinopathyImmune-related EndocrinopathyRadionuclide Thyroid ScintigraphyRecurrenceSecondary Adrenal InsufficiencyThyroiditis Imaging Patterns
Nivolumab-induced multiple organ immune-related adverse events (irAEs) have been described in some case reports. The symptoms of endocrinological irAEs are especially nonspecific. A 63-year-old man with a postoperative recurrence of pulmonary adenocarcinoma who was treated with nivolumab presented fever, anorexia and fatigue after the 7th cycle. He underwent a rapid adrenocorticotrophic hormone test, four-hormone tolerance test and thyroid gland scintigraphy. The results were consistent with destructive thyroiditis, hypophysitis and secondary adrenal insufficiency. Nivolumab was restarted following glucocorticoid and thyroid hormone replacement treatment. When a patient presents nonspecific symptoms, the possibility of endocrinological irAEs should be considered as it may enable their early detection.
13
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Myasthenic crisis and polymyositis induced by one dose of nivolumab
Toshihiro Kimura, Satoshi Fukushima, Azusa Miyashita et al. · Cancer Science · 2016 · 194 citations · Full text